Press Releases April 12, 2026 08:00 PM

Celldex to Present at Upcoming Investor Conference

Celldex to participate in fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
CLDX

Celldex Therapeutics announced that its management will present and participate in a fireside chat at the upcoming H.C. Wainwright Inflammatory Skin Disease Virtual Conference. The event will be webcast and replays will be available for 90 days, highlighting Celldex's commitment to advancing novel antibody-based immunology therapies targeting allergic, inflammatory, and autoimmune disorders.

Celldex to Present at Upcoming Investor Conference
CLDX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Celldex management will engage with investors and industry participants during the April 14 virtual conference.
  • The company focuses on developing antibody-based therapies targeting immune system pathways for inflammatory and autoimmune diseases.
  • The webcast presentation aims to enhance investor awareness and showcase Celldex's progress in immunology drug development.

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET.

The webcast of the presentations will be available on the "Events & Presentations" page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com


Risks

  • Clinical and regulatory risks inherent in developing novel immunology therapies could affect future progress.
  • Market reception and competitive landscape in inflammatory and autoimmune disease treatments may impact Celldex's growth.
  • Dependence on successful translation of research into effective therapies presents uncertainty in timelines and outcomes.

More from Press Releases

Nuwellis Announces Closing of $6.0 Million Registered Public Offering Jun 8, 2026 Grupo Aeroportuario del Pacifico Publishes its 2025 Sustainability Report Jun 8, 2026 Cipher Digital Inc. Announces Pricing of $810.0 Million of Senior Secured Notes Jun 8, 2026 Ocean Capital Acquisition Corporation Prices $100 Million Initial Public Offering Jun 8, 2026 Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation Jun 8, 2026